Chaim Lebovits, BrainStorm Cell Therapeutics CEO

Brain­Storm gets FDA ad­comm for ALS drug af­ter failed tri­al and RTF

Brain­Storm Cell Ther­a­peu­tics has had a rocky road try­ing to get its ALS treat­ment through to the FDA, in­clud­ing a par­tic­u­lar­ly dif­fi­cult set­back af­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.